1. A method of treating non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers syndrome, comprising administering an effective amount of an inhibitor of TOR-kinase patient with non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers syndrome, characterized by loss or mutation of a gene or protein relative to the wild-LKB1 tipa.2. A method of treating non-small cell lung carcinoma, or cervical cancer comprising carcinoma screening or cancer patient to loss or presence of gene mutation or LKB1 protein relative to wild-type and administering an effective amount of TOR-kinase patient inhibitor with non-small cell lung carcinoma, or cervical cancer characterized by loss or LKB1.3 gene mutation or protein. Method prognosis of probability of a patients non-small cell lung carcinoma, or cervical cancer treatable inhibitors of TOR-kinase comprising carcinoma screening or malignant said patients tumor to loss or presence of gene mutation or LKB1 protein relative to the wild type, where the loss or the presence of a gene or protein mutations LKB1 suggests an increased likelihood that TOR-inhibitors therapy kinase will act on these non-small cell lung carcinoma, or cervical matki.4. Method prediction of therapeutic efficacy for treating a patient with non-small cell lung carcinoma, or cervical cancer inhibitor of TOR-kinase comprising carcinoma screening or malignant tumor of said patient to loss or having mutations or LKB1 protein relative to the wild type, where the loss or the presence of mutations or LKB1 protein are
